Motus GI Holdings surges on promising data from gastro device

Motus GI Holdings

17/05/2023 15:05

** Shares of medtech firm Motus GI Holdings Inc  MOTS.O 
surge 87.5% to $1.35
    ** Co completes first clinical study of its device, Pure-Vu
Gen 4 Gastro, which is designed to improve a physician's
visualization while identifying upper gastrointestinal (GI)
bleeding 
    ** Motus GI says Pure-Vu Gastro achieves high usability
scores in supporting upper endoscopy procedures with first time
users
    ** The data from the study will support co's submission of
marketing application to U.S. FDA, which remains on track for
the device in Q4 2023
    ** Including session gains, stock had risen ~79% YTD

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))